Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of SRSD107 in Healthy Participants
NCT06116617Phase 1Completed
- Sponsor
- Sirius Therapeutics
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SRSD107 in thrombosis (6 arms), sponsored by Sirius Therapeutics. Primary endpoints: Proportion of adverse events (AEs) and Proportion of Serious Adverse Events (SAEs). Started Jan 2024; status: completed.
02
Drugs
SRSD107
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT06116617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116617.